The Challenge

Overview

Curebase entered the decentralized clinical trial industry with one major competitive differentiator: A platform that enables patients to participate in clinical trials from the comfort of their own homes and with their own primary care physicians. The concept was based on the founder’s desire to make clinical research accessible for everyone, not just those living in close proximity to a research site. Curebase selected Amendola Communications to provide strategic counsel, media relations, and content development to help drive brand and concept awareness for its unique approach in a highly competitive market.

Insight

Clinical trials traditionally have been conducted at academic healthcare institutions or, more recently, through decentralized clinical trials (DCT). Never before, however, has it been possible for people to use their own doctors while participating in a trial. With the growth of DCTs, this space is flooded with large companies with lots of money and strong ties to top academic institutions. Curebase turned to Amendola to raise awareness among healthcare stakeholders and media of the company’s groundbreaking solution and to capture market share.

Solution

Amendola coined the term “BYOP,” or “Bring Your Own Physician,” clinical trials, as a play off the “BYOD” (Bring Your Own Device) acronym that is well known in the business world. Building off Curebase’s rapidly growing industry partnerships, successful emergency use authorization (EUA) initiatives during the pandemic, and industry trends, Amendola has helped amplify the Curebase differentiator – its “BYOP” message – in the marketplace. As a result, this small up-and-comer is now often mentioned alongside the industry’s biggest DCT technology players in media coverage and analyst reports. Additionally, Curebase is leveraging BYOP as a differentiator that has enabled the brand to introduce trials directly to physicians and patients regardless of geographic location, greatly expanding its global opportunities.